PRASFIT-Elective Study: PRASugrel Compared to Clopidogrel For Japanese PatIenTs with Coronary Artery Disease Undergoing Elective PCI

Trial Profile

PRASFIT-Elective Study: PRASugrel Compared to Clopidogrel For Japanese PatIenTs with Coronary Artery Disease Undergoing Elective PCI

Completed
Phase of Trial: Phase III

Latest Information Update: 02 Jun 2016

At a glance

  • Drugs Prasugrel (Primary) ; Aspirin; Clopidogrel
  • Indications Angina pectoris; Coronary artery disease; Embolism and thrombosis; Myocardial infarction
  • Focus Registrational; Therapeutic Use
  • Acronyms PRASFIT-Elective
  • Sponsors Daiichi Sankyo Company; Ube Industries
  • Most Recent Events

    • 24 Mar 2014 The Ministry of Health, Labour and Welfare in Japan has approved prasugrel in patients undergoing PCI based on results from this trial and and the PRASFIT-Elective trial according to a Daiichi Sankyo Company media release.
    • 12 Jul 2013 Primary endpoint 'Cardiovascular-event-rate' has been met, according resutls reported in a Daiichi Sankyo Company media release.
    • 12 Jul 2013 An NDA has been submitted to the Ministry of Health, Labour and Welfare in Japan for the treatment of IHD in patients undergoing PCI based on the results of the PRASFIT-ACS and PRASFIT-Elective studies, according to a Daiichi Sankyo Company media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top